title: [Clinical analysis of amphotericin B in the treatment of invasive fungal infections in 121 patients with hematologic diseases].
abstract: OBJECTIVE
  To observe the efficacy and safety of amphotericin B for treatment of invasive fungal infections (IFI) in patients with hematologic diseases.
  
  
  METHODS
  121 patients were given amphotericin B 5 -50 mg/d for 5 - 101 d with a median of 19 d.
  
  
  RESULTS
  The clinical efficacy rate was 67.3%, and fungal elimination rate 66.7%. The adverse events included rigor and fever, hypokalaemia, hepatic damage, nephrotoxicity, nausea and vomiting, phlebitis and teeter.
  
  
  CONCLUSIONS
  Amphotericin B is still a high-efficiency drug in the treatment of IFI, although it has many side effects. With monitoring of hepatic and renal function, it is still a relatively safe and effective drug.
authors.affiliation: Department of Hematology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Jia
authors.forename: Mei
authors.initials: M
authors.lastname: Huang
authors.forename: Wen-Li
authors.initials: WL
authors.lastname: Liu
authors.forename: Yi-Cheng
authors.initials: YC
authors.lastname: Zhang
authors.forename: Han-Ying
authors.initials: HY
authors.lastname: Sun
authors.forename: Dong-Hua
authors.initials: DH
authors.lastname: Zhang
authors.forename: Jin-Niu
authors.initials: JN
authors.lastname: Deng
authors.forename: Jian-Feng
authors.initials: JF
authors.lastname: Zhou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B